Navigation Links
Cardiac Science Initiates Voluntary Field Corrective Action of Certain AEDs
Date:10/13/2008

No interruption to shipments or service to new or existing customers.

BOTHELL, Wash., Oct. 13 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX) announced today that it has initiated a worldwide voluntary field corrective action of certain automated external defibrillators (AEDs) manufactured between August 2006 and March 2007. Some AEDs manufactured in this time frame may have a component whose performance doesn't match the factory software settings. Under a particular set of conditions, the software places the AED into a "Service Required" mode.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

To remedy this and complete the corrective action, Cardiac Science is providing a user-installable software update to affected customers and distributors.

"This voluntary field action is an opportunity for Cardiac Science to demonstrate that we stand behind every one of our products," said John Hinson, chief executive officer.

Cardiac Science has begun notifying distributors and customers with affected devices and is shipping software updates to each. The instructions and additional information regarding the affected units are also available at http://www.cardiacscience.com/AEDUpdate. Customers can also call 1.877.502.2673 or e-mail aedqs99@cardiacsience.com.

Until the updates arrive, customers should keep their AEDs in service. This issue is typically identified in daily self-test, however, there is a remote possibility of occurrence while attempting to provide defibrillation. The Company has received two complaints related to this issue during use.

The company expects to take a pre-tax charge of between $0.8 million and $1.0 million in the third quarter of 2008 relating to the estimated costs associated with this voluntary action. This action will not affect the company's AED manufacturing, shipping schedules, or service support to current or new customers.

"While this unanticipated charge will obviously have an impact on third quarter earnings, we presently expect that we will still finish the full year within the range of our earlier guidance, though we are now more comfortable with the lower end of that range," said Mike Matysik, chief financial officer. Cardiac Science expects to announce its third quarter 2008 results in late October and will provide an update on guidance for the balance of the year at that time.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, those that refer to full-year guidance for Cardiac Science Corporation's future revenue and profits. These statements and their underlying assumptions involve a number of risks and uncertainties and are not guarantees of future performance. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward looking. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks that are more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2007. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For more information,

Company Contact: Investor Contact: Media Contact:

Mike Matysik Doug Sherk Christopher Gale

Cardiac Science Jenifer Kirtland EVC Group, Inc.

Corporation EVC Group, Inc. (201) 646-5431

Sr. Vice President (415) 896-6820 (203) 570-4681

and CFO cgale@evcgroup.com

(425) 402-2009 CSCX-G


'/>"/>
SOURCE Cardiac Science Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Advanced Circulatory Systems Receives $1.5 Million From NIH for Study of Cardiac Arrest Resuscitation Techniques
2. 3 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques
3. Ganatra Family Gift to Boost Cardiac Technology at Levine Childrens Hospital
4. New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest
5. UHN becomes a world leader in medical imaging for stroke, cancer and cardiac patients
6. Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome
7. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center First in the Nation to Use a New Generation of Medical Robots for Complex Electrophysiology Mapping Procedures
8. Making Sudden Cardiac Arrest a National Health Priority: National Medical Association Issues White Paper on Sudden Cardiac Arrest
9. Freescale and Monebo Launch ECG-on-a-Chip Platform Solution to Aid Heart Monitoring : Advanced Hardware and Software Technology Designed to Enable More Efficient and Higher Quality Cardiac Care
10. ELS Plus CPR Boosts Blood Flow After Cardiac Arrest
11. Screening Athletes Could Cut Sudden Cardiac Death Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: